` EPRX (Eupraxia Pharmaceuticals Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

EPRX
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, EPRX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +78% compared to the S&P TSX Composite Index (Canada)'s +25% growth.

Stocks Performance
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Eupraxia Pharmaceuticals Inc vs Peers

S&P TSX Composite Index (Canada)
EPRX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Eupraxia Pharmaceuticals Inc
Glance View

Market Cap
436.7m CAD
Industry
Biotechnology

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

EPRX Intrinsic Value
Not Available
Back to Top